We designed the project to validate CRISPR/Cas9-based gene editing combined with AAV-based delivery for correction of the most common MECP2 mutations both in vitro and in vivo.
The project aims to validate CRISPR/Cas9-based gene editing combined with AAV-based delivery for correction of the most common MECP2 mutations both in vitro and in vivo. The laboratory of the principal investigator is an active member of the European Reference Network for rare malformation syndromes and rare intellectual and neurodevelopmental disorders (ERN-ITHACA).
Study Type
OBSERVATIONAL
Enrollment
40
Testing of gene editing efficiency in vitro in human cellular models derived from patients
University of Siena
Siena, Siena, Italy
RECRUITINGEditing efficiency
Percentage of gene editing achieved for each mutation
Time frame: 3 years
Editing specificity
Evaluation of off-targets
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.